top of page

Johnson and Johnson acquired Momenta Pharmaceuticals, aims to strength immunology profile

Johnson and Johnson announced that it will acquire Momenta Pharmaceuticals for an all cash transaction worth of $6.5 billion.

Momenta Pharmaceuticals is involved developing novel therapies for immunological diseases.

Also read: Novartis Kesimpta approved for relapsing multiple sclerosis in the US

Also read: Japan's healthcare system

The transaction will help Janssen to retain the global rights for nipocalimab (M281), drug which can potentially target FcRn antibody. The drug is in the Phase 2/3 trial for autoimmune hemolytic anemia. The drug is the Phase 2 trials for haemolytic diseases of new born and myasthenia gravis. Janssen expects a peak sales of more than one billion for nipocalimab. Company’s other product M254 is in the Phase 2 trial for immune thrombocytopenic purpura (ITP), and in Phase 1 trial for chronic inflammatory demyelination polyneuropathy.

Also read: Amgen’s Kyprolis and Janssen’s Darzalex combination approved by the US FDA for multiple myeloma

Also read: AZ received one more approval in Japan, received approval of Imfinzi for SCLC

Momenta Pharmaceuticals has developed expertise in FcRn mechanism, as it is believed to support number of autoantibody-driven conditions. Myasthenia gravis, hemolytic diseases new born, warm autoimmune hemolytic anemia, and other serious dermatologic, rheumatic, neurologic, hematologic and renal diseases are common autoantibody-driven diseases.

Also read: US Healthcare System

With the acquisition, Janssen expects to expands its portfolio in maternal-fetal disorders neuro-inflammatory disorders, rheumatology, dermatology and autoimmune hematology.

Janssen has announced that it will retain Momenta’s presence in Cambridge, Massachusetts.

Also read: Gilead’s CAR-T cell therapy approved for Relapsed or Refractory Mantle Cell Lymphoma


For pipeline, market overview, SLRs, and market access reports (syndicate and customised) please write to

For all syndicate reports: Click here

bottom of page